SynthesisNature communications2022
Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources.
Synthesis in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 4 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis.Blood advances · 2023Pooled it
- Pooled it
- A systematic review on impact of SARS-CoV-2 infection.Microbiological research · 2023Pooled it
- COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis.JAMA network open · 2023Pooled it
- SARS-CoV-2 convalescent plasma for the controlled clinical trial "COVIC-19": Experience from collection of very high-titer plasma from superimmunized individuals.Transfusion · 2025Trial
- Patient and donor antibody profiles in early COVID-19 convalescent plasma therapy in the COnV-ert trial.Frontiers in immunology · 2025Trial
- Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial.JCI insight · 2024Trial
- One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients.The Journal of clinical investigation · 2022Trial
- Determinants of success and failure of antibody-based strategies against respiratory viruses: insights from RSV and SARS-CoV-2.Frontiers in immunology · 2026Review
- COVID-19 convalescent plasma safety and efficacy analysis for biologics license application approval.Expert review of anti-infective therapy · 2026Review
- Time-Dependent Outcomes of Convalescent Plasma in Early COVID-19: A Single-Center Cohort with a Host-Pathogen Perspective.Pathogens (Basel, Switzerland) · 2025Article
- Wastewater sequencing from a rural community enables identification of widespread adaptive mutations in a SARS-CoV-2 alpha variant.Scientific reports · 2025Article
- Structure and function of an unusual R452-dependent monoclonal antibody against SARS-CoV-2.Journal of virology · 2025Article
- A Surrogate Enzyme-Linked Immunosorbent Assay to Select High-Titer Human Convalescent Plasma for Treating Immunocompromised Patients Infected With Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern.The Journal of infectious diseases · 2025Article
- Convalescent Plasma and Other Antibody Therapies for Infectious Diseases-Lessons Learned from COVID-19 and Future Prospects.Current topics in microbiology and immunology · 2025Review
- Convalescent Plasma for Immunocompromised Patients.Current topics in microbiology and immunology · 2025Review
- Convalescent plasma therapy for COVID-19 - Donor selection strategies and establishment of a plasma bank.New microbes and new infections · 2024Article
- COVID-19 therapeutics.Clinical microbiology reviews · 2024Review
- The presence of broadly neutralizing anti-SARS-CoV-2 RBD antibodies elicited by primary series and booster dose of COVID-19 vaccine.PLoS pathogens · 2024Article
- SARS-CoV-2 variant of concern fitness and adaptation in primary human airway epithelia.Cell reports · 2024Article
Corrections and comments
- Update of
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
The latest SARS-CoV-2 variant of concern Omicron, with its immune escape from therapeutic anti-Spike monoclonal antibodies and WA-1 vaccine-elicited sera, demonstrates the continued relevance of COVID-19 convalescent plasma (CCP) therapies. Lessons learnt from previous usage of CCP suggests focusing on early outpatients and immunocompromised recipients, with high neutralizing antibody titer units. Here, we systematically review Omicron-neutralizing plasma activity data, and report that approximately 47% (424/902) of CCP samples from unvaccinated pre-Omicron donors neutralizes Omicron BA.1 with a very low geometric mean of geometric mean titers for 50% neutralization GM(GMT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.